FAA Targets Clearer Cannabis Policies for Air Traffic Controllers and Pilots

Federal aviation regulators are moving to craft scientifically grounded standards for cannabis use among pilots and air traffic controllers, responding to recent shifts in national marijuana policy that officials say have introduced new operational uncertainties.

In April, the Justice Department and Drug Enforcement Administration reclassified FDA-approved marijuana products and cannabis distributed under qualifying state medical licenses as Schedule III substances. Recreational marijuana remains classified as Schedule I. An administrative hearing on whether to extend Schedule III status more broadly concluded in mid-July, with final briefs submitted in August and a conclusive ruling still pending.

The change has created a split regulatory picture. Medical cannabis in approved forms now carries federal recognition of therapeutic value, yet Department of Transportation testing rules and Federal Aviation Administration medical certification requirements have not been altered. Safety-sensitive aviation workers, including pilots and air traffic control specialists, continue to face a complete ban on marijuana. A positive test result remains disqualifying regardless of any state medical authorization.

FAA officials have pointed to an emerging mismatch. Greater availability and social acceptance of cannabis raise the chance of use among aviation personnel, complicate honest disclosure, and leave the agency without reliable benchmarks for determining when any residual effects have fully cleared. Existing rules simply prohibit the substance; they do not define a science-based window after which an individual can be considered both unimpaired and compliant with federal drug-testing standards.

That gap is the focus of a new initiative. The FAA’s Office of Aerospace Medicine is working with the National Academies of Sciences, Engineering, and Medicine to organize a series of closed expert meetings across 2026 and 2027. Funded at just over $200,000, the four sessions will examine impairment duration and variability, detectability through testing, cognitive performance monitoring, and methods for translating research into practical policy. Participants will include specialists in pharmacokinetics, operational risk, and regulatory design.

The central question the group will address is precise: After cannabis consumption, what elapsed time provides assurance of both operational fitness and adherence to DOT testing requirements? Discussions will also cover screening approaches for recent and longer-term use among pilots and ATCS. The meetings will not generate a public report but are expected to equip the FAA with the evidence base needed to refine its policies over the following 12 to 18 months.

In the meantime, current prohibitions remain fully enforceable. The agency has reaffirmed that aviation safety takes precedence and that no interim exceptions apply. The effort illustrates the challenge of maintaining uncompromising safety standards while federal cannabis policy continues to evolve.